RxDoctor Payments Data

Jamin Brahmbhatt, MD

Urology · Clermont, FLNPI 1073714267

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 77.2% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2024 at $14,093 and has fallen 86.6% since, to $1,883 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,625in general payments, 2019–2025

Across 282 payments — averaging $126.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Axonics, Inc.$3K
  • Stryker$1K
  • Pfizer$876
  • Astellas Pharma US Inc$316
  • Endo Pharmaceuticals Inc.$281
  • plus $3K from 45 others

What the payments were for

  • Consulting fees$17,72050%
  • Speaking & faculty fees$8,88325%
  • Travel & lodging$2,1866%
  • Food & beverage$6,60519%
  • Education$2321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,625 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.

See all urology providers in Florida →

Medicare billing

Part B allowed, 2024
$301,222
Medicare patients
703
Services billed
21,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron52$31,385
GemtesaVibegron24$14,907
Tolterodine Tartrate ErTolterodine Tartrate12$2,101
Tamsulosin Hcl190$1,814
Finasteride125$1,422
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim194$612
Gentamicin Sulfate33$405
Oxybutynin Chloride64$387
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$220
Doxycycline Hyclate15$199
Cephalexin54$186
Ciprofloxacin Hcl14$123
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$73
Fluconazole11$70
Tramadol Hcl35$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$316$31,38552 claims
Sumitomo Pharma America, Inc.Gemtesa$79$14,90724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.

Other urology in Clermont

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →